Despite the lack of standardization among MDT groups at a variety of institutions, all reported literature supports a positive relationship between improved care coordination, adherence to clinical guidelines, reduced time to treatment, and improved survival following MDT discussion. This, taken in conjunction with the plethora of similar survival results among non-H&N (i.e., breast, lung, colorectal) cancers, has resulted in a new standard of care advocating for MDT for all H&N cancer patients. Further studies are required to better assess resource allocation, cost-effectiveness, and quality-of-life outcomes. Thus, all H&N cancer patients requiring single or multimodality therapy for advanced H&N cancer should be presented at MDT conference (Laryngoscope. 2018;128:1257–1258).